$TCRT
Alaunos Therapeutics, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022024695 Filed on November 14, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $11.00K $2.911M $398.0K
YoY Change 631.41%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.925M $3.282M $8.173M
YoY Change 39.62% -59.84% 28.71%
% of Gross Profit
Research & Development $5.607M $7.893M $14.52M
YoY Change -31.76% -45.64% 3.96%
% of Gross Profit
Depreciation & Amortization $694.0K $691.0K $673.0K
YoY Change -1.56% 2.67% -4.94%
% of Gross Profit
Operating Expenses $8.532M $11.18M $22.69M
YoY Change -17.25% -50.76% 11.68%
Operating Profit -$8.264M -$22.30M
YoY Change -62.94% 9.72%
Interest Expense -$888.0K $841.0K -$444.0K
YoY Change 20.33% -289.41%
% of Operating Profit
Other Income/Expense, Net $250.0K -$587.0K -$437.0K
YoY Change -5100.0% 34.32% -7383.33%
Pretax Income -$9.159M -$8.851M -$22.73M
YoY Change -22.34% -61.07% 11.88%
Income Tax
% Of Pretax Income
Net Earnings -$9.159M -$8.851M -$22.73M
YoY Change -22.34% -61.07% 11.9%
Net Earnings / Revenue -83263.64% -304.05% -5711.81%
Basic Earnings Per Share -$0.04 -$0.11
Diluted Earnings Per Share -$0.04 -$0.04 -$106.0K
COMMON SHARES
Basic Shares Outstanding 216.2M 216.2M 215.6M
Diluted Shares Outstanding 215.1M 214.5M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $39.06M $37.81M $91.73M
YoY Change -48.64% -58.78% -32.29%
Cash & Equivalents $39.06M $37.80M $91.70M
Short-Term Investments
Other Short-Term Assets $14.74M $14.79M $3.319M
YoY Change 784.57% 345.53% -76.58%
Inventory
Prepaid Expenses
Receivables $4.000K $2.911M $1.510M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $53.80M $55.51M $96.55M
YoY Change -31.75% -42.51% -37.74%
LONG-TERM ASSETS
Property, Plant & Equipment $8.460M $9.050M $11.66M
YoY Change -22.68% -22.4% 17.24%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $500.0K $500.0K $2.000K
YoY Change -20.76% 24900.0% -99.77%
Total Long-Term Assets $11.14M $11.84M $17.21M
YoY Change -30.54% -31.2% 58.99%
TOTAL ASSETS
Total Short-Term Assets $53.80M $55.51M $96.55M
Total Long-Term Assets $11.14M $11.84M $17.21M
Total Assets $64.94M $67.34M $113.8M
YoY Change -31.55% -40.8% -31.42%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.389M $1.984M $1.463M
YoY Change 1.54% 35.61% -44.14%
Accrued Expenses $5.454M $7.675M $13.96M
YoY Change -10.24% -45.03% -16.4%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $16.77M $22.67M $12.04M
YoY Change 113.08% 88.32%
Total Short-Term Liabilities $24.17M $32.87M $28.17M
YoY Change 50.65% 16.67% 45.82%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $12.17M
YoY Change -100.0% -100.0%
Other Long-Term Liabilities $28.00K $28.00K $4.708M
YoY Change -99.41% 184.47%
Total Long-Term Liabilities $28.00K $28.00K $12.17M
YoY Change -99.83% -99.77% 635.59%
TOTAL LIABILITIES
Total Short-Term Liabilities $24.17M $32.87M $28.17M
Total Long-Term Liabilities $28.00K $28.00K $12.17M
Total Liabilities $26.38M $35.23M $45.06M
YoY Change -28.33% -21.8% 114.79%
SHAREHOLDERS EQUITY
Retained Earnings -$880.6M -$871.5M -$831.1M
YoY Change 4.48% 4.86%
Common Stock $919.2M $903.6M $899.8M
YoY Change 2.03% 0.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $38.56M $32.11M $68.71M
YoY Change
Total Liabilities & Shareholders Equity $64.94M $67.34M $113.8M
YoY Change -31.55% -40.8% -31.42%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$9.159M -$8.851M -$22.73M
YoY Change -22.34% -61.07% 11.9%
Depreciation, Depletion And Amortization $694.0K $691.0K $673.0K
YoY Change -1.56% 2.67% -4.94%
Cash From Operating Activities -$7.130M -$6.145M -$9.577M
YoY Change -52.86% -35.84% -76.04%
INVESTING ACTIVITIES
Capital Expenditures $116.0K -$14.00K -$370.0K
YoY Change -132.31% -96.22% -93.85%
Acquisitions
YoY Change
Other Investing Activities $23.00K
YoY Change
Cash From Investing Activities -$93.00K -$14.00K -$370.0K
YoY Change -74.09% -96.22% -93.85%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 8.474M -2.107M 24.93M
YoY Change -4655.91% -108.45% -75.5%
NET CHANGE
Cash From Operating Activities -7.130M -6.145M -9.577M
Cash From Investing Activities -93.00K -14.00K -370.0K
Cash From Financing Activities 8.474M -2.107M 24.93M
Net Change In Cash 1.251M -8.266M 14.98M
YoY Change -107.98% -155.18% -73.12%
FREE CASH FLOW
Cash From Operating Activities -$7.130M -$6.145M -$9.577M
Capital Expenditures $116.0K -$14.00K -$370.0K
Free Cash Flow -$7.246M -$6.131M -$9.207M
YoY Change -50.93% -33.41% -72.89%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001107421
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-33038
dei Entity Registrant Name
EntityRegistrantName
Alaunos Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
84-1475642
dei Entity Address Address Line1
EntityAddressAddressLine1
8030 El Rio Street
dei Entity Address City Or Town
EntityAddressCityOrTown
Houston
dei Entity Address State Or Province
EntityAddressStateOrProvince
TX
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
77054
dei City Area Code
CityAreaCode
346
dei Local Phone Number
LocalPhoneNumber
355-4099
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
TCRT
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
216182042
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37807000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
76054000
CY2022Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
13938000
CY2021Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
0
CY2022Q3 us-gaap Receivables Net Current
ReceivablesNetCurrent
2911000
CY2021Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
1111000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
849000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1666000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
55505000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
78831000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
9050000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
10941000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2247000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
4420000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
216182042
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
216182042
CY2022Q3 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
42000
CY2021Q4 us-gaap Deposits Assets Noncurrent
DepositsAssetsNoncurrent
42000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
500000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
631000
CY2022Q3 us-gaap Assets
Assets
67344000
CY2021Q4 us-gaap Assets
Assets
94865000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1984000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1368000
CY2022Q3 us-gaap Long Term Debt Current
LongTermDebtCurrent
22668000
CY2021Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
7868000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7675000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6076000
CY2022Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
542000
CY2021Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
729000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
32869000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
16041000
CY2022Q3 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
0
CY2021Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
16250000
CY2022Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
2334000
CY2021Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
4518000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
28000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0
CY2022Q3 us-gaap Liabilities
Liabilities
35231000
CY2021Q4 us-gaap Liabilities
Liabilities
36809000
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
420000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
216127443
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
216127443
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
216000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
216000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
903365000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
900693000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-871468000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-842852000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
32113000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
58057000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
67344000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
94865000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2911000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
398000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2911000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
398000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7893000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
14521000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19411000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
41427000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3282000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8173000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10217000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
25469000
CY2022Q3 tcrt Gain Loss On Operating Lease Modification
GainLossOnOperatingLeaseModification
0
CY2021Q3 tcrt Gain Loss On Operating Lease Modification
GainLossOnOperatingLeaseModification
0
tcrt Gain Loss On Operating Lease Modification
GainLossOnOperatingLeaseModification
133000
tcrt Gain Loss On Operating Lease Modification
GainLossOnOperatingLeaseModification
0
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
11175000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
22694000
us-gaap Operating Expenses
OperatingExpenses
29495000
us-gaap Operating Expenses
OperatingExpenses
66896000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8264000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-22296000
us-gaap Operating Income Loss
OperatingIncomeLoss
-26584000
us-gaap Operating Income Loss
OperatingIncomeLoss
-66498000
CY2022Q3 us-gaap Interest Expense
InterestExpense
841000
CY2021Q3 us-gaap Interest Expense
InterestExpense
444000
us-gaap Interest Expense
InterestExpense
2266000
us-gaap Interest Expense
InterestExpense
444000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
254000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
7000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
279000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-587000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-437000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1987000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-459000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8851000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-22733000
us-gaap Net Income Loss
NetIncomeLoss
-28571000
us-gaap Net Income Loss
NetIncomeLoss
-66957000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.04
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.04
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.11
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.11
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.31
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.31
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
215098995
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
215098995
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
214542465
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
214542465
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
215015377
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
148000
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
215015377
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
214310349
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
214310349
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
40180000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
808000
CY2022Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21000
CY2022Q3 us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
45000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-8851000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
32113000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
58057000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2651000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
21000
us-gaap Stock Repurchased During Period Value
StockRepurchasedDuringPeriodValue
45000
us-gaap Net Income Loss
NetIncomeLoss
-28571000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
32113000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
88281000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2371000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
788000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-22733000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
68707000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
123982000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
9857000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1037000
us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
788000
us-gaap Net Income Loss
NetIncomeLoss
-66957000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
68707000
us-gaap Net Income Loss
NetIncomeLoss
-28571000
us-gaap Net Income Loss
NetIncomeLoss
-66957000
us-gaap Depreciation
Depreciation
2065000
us-gaap Depreciation
Depreciation
1892000
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
634000
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
2651000
us-gaap Employee Benefits And Share Based Compensation Noncash
EmployeeBenefitsAndShareBasedCompensationNoncash
9857000
tcrt Increase Decrease In Right Of Use Asset
IncreaseDecreaseInRightOfUseAsset
-2306000
tcrt Increase Decrease In Right Of Use Asset
IncreaseDecreaseInRightOfUseAsset
529000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
133000
us-gaap Gain Loss On Termination Of Lease
GainLossOnTerminationOfLease
0
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
1800000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-3155000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-817000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-7646000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-131000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-508000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
616000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
503000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1525000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-3169000
tcrt Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
-2371000
tcrt Increase Decrease In Lease Liabilities
IncreaseDecreaseInLeaseLiabilities
604000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
28000
us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
0
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22102000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-46342000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
100000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-871500000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2964000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-100000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-2964000
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
25000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
0
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
75000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
21000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
1037000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
45000
us-gaap Payments For Repurchase Of Common Stock
PaymentsForRepurchaseOfCommonStock
0
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
2083000
us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-2107000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25962000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-24309000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-23344000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
76054000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
115069000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
51745000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
91725000
us-gaap Interest Paid Net
InterestPaidNet
1603000
us-gaap Interest Paid Net
InterestPaidNet
136000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
74000
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
348000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
37800000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
13900000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">statements </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">and the reported amounts of revenues and expenses during the reporting period. Although the Company regularly assesses these estimates, actual results could differ from those estimates. Changes in estimates are recorded in the period in which they become known.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2022Q3 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
22668000
CY2021Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
24118000
us-gaap Debt Instrument Basis Spread On Variable Rate1
DebtInstrumentBasisSpreadOnVariableRate1
0.045
tcrt Interest Expense Amortized Date
InterestExpenseAmortizedDate
2023-08-01
CY2022Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
800000
us-gaap Interest Expense Debt
InterestExpenseDebt
2300000
CY2021Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
400000
us-gaap Interest Expense Debt
InterestExpenseDebt
400000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
34485557
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
35386620
tcrt Gain Loss On Modification Of Lease
GainLossOnModificationOfLease
100000
CY2022Q3 tcrt Sublease Area
SubleaseArea
4772
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The term of the sub-sublease is from July 1, 2022 to June 30, 2025 and provides the sub-subtenant with an option to extend through to July 31, 2026
CY2022Q3 us-gaap Share Based Compensation
ShareBasedCompensation
808000
CY2021Q3 us-gaap Share Based Compensation
ShareBasedCompensation
2371000
us-gaap Share Based Compensation
ShareBasedCompensation
2651000
us-gaap Share Based Compensation
ShareBasedCompensation
9857000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
1275000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.52
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
4667500
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.67
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
2755000
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.08
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
7150438
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.91
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0294
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0362
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0089
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0096
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0163
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0362
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0050
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0115
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.8243
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8589
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7253
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7284
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7449
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.8589
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.7253
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.7480
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10665869
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
2.87
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod
4667500
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.08
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
26250
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0.80
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
4683904
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
3.40
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10623215
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
1.85
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y3M7D
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
3572000
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3211631
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y6M10D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
15245494
CY2022Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
2.69
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P7Y3D
CY2022Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
510000
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
4410312
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.85
CY2019Q3 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
52500000

Files In Submission

Name View Source Status
0000950170-22-024695-index-headers.html Edgar Link pending
0000950170-22-024695-index.html Edgar Link pending
0000950170-22-024695.txt Edgar Link pending
0000950170-22-024695-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img159889792_0.jpg Edgar Link pending
img159889792_1.jpg Edgar Link pending
img159889792_2.jpg Edgar Link pending
img159889792_3.jpg Edgar Link pending
img159889792_4.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tcrt-20220930.htm Edgar Link pending
tcrt-20220930.xsd Edgar Link pending
tcrt-ex31_1.htm Edgar Link pending
tcrt-ex32_1.htm Edgar Link pending
tcrt-ex3_1.htm Edgar Link pending
tcrt-20220930_lab.xml Edgar Link unprocessable
tcrt-20220930_cal.xml Edgar Link unprocessable
tcrt-20220930_pre.xml Edgar Link unprocessable
tcrt-20220930_def.xml Edgar Link unprocessable
tcrt-20220930_htm.xml Edgar Link completed